Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 42
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Int J Mol Sci ; 25(3)2024 Jan 28.
Article in English | MEDLINE | ID: mdl-38338886

ABSTRACT

The COVID-19 pandemic has had a significant and enduring influence on global health, including maternal and fetal well-being. Evidence suggests that placental dysfunction is a potential consequence of SARS-CoV-2 infection during pregnancy, which may result in adverse outcomes such as preeclampsia and preterm birth. However, the molecular mechanisms underlying this association remain unclear, and it is uncertain whether a mature placenta can protect the fetus from SARS-CoV-2 infection. To address the above gap, we conducted a transcriptome-based study of the placenta in both maternal and fetal compartments. We collected placental samples from 16 women immediately after term delivery, seven of which had SARS-CoV-2 infection confirmed by PCR before parturition. Notably, we did not detect any viral load in either the maternal or fetal compartments of the placenta, regardless of symptomatic status. We separately extracted total RNA from placental tissues from maternal and fetal compartments, constructed cDNA libraries, and sequenced them to assess mRNA. Our analysis revealed 635 differentially expressed genes when a false discovery rate (FDR ≤ 0.05) was applied in the maternal placental tissue, with 518 upregulated and 117 downregulated genes in the SARS-CoV-2-positive women (n = 6) compared with the healthy SARS-CoV-2-negative women (n = 8). In contrast, the fetal compartment did not exhibit any significant changes in gene expression with SARS-CoV-2 infection. We observed a significant downregulation of nine genes belonging to the pregnancy-specific glycoprotein related to the immunoglobulin superfamily in the maternal compartment with active SARS-CoV-2 infection (fold change range from -13.70 to -5.28; FDR ≤ 0.01). Additionally, comparing symptomatic women with healthy women, we identified 1788 DEGs. Furthermore, a signaling pathway enrichment analysis revealed that pathways related to oxidative phosphorylation, insulin secretion, cortisol synthesis, estrogen signaling, oxytocin signaling, antigen processing, and presentation were altered significantly in symptomatic women. Overall, our study sheds light on the molecular mechanisms underlying the reported clinical risks of preeclampsia and preterm delivery in women with SARS-CoV-2 infection. Nonetheless, studies with larger sample sizes are warranted to further deepen our understanding of the molecular mechanisms of the placenta's anti-viral effects in maternal SARS-CoV-2 infection.


Subject(s)
COVID-19 , Pre-Eclampsia , Premature Birth , Infant, Newborn , Pregnancy , Humans , Female , Placenta , Pregnancy Trimester, Third , Pandemics , COVID-19/genetics , SARS-CoV-2 , Gene Expression Profiling , Infectious Disease Transmission, Vertical
2.
Invest New Drugs ; 40(1): 209-214, 2022 02.
Article in English | MEDLINE | ID: mdl-34398354

ABSTRACT

Immunotherapy has been a revolutionary innovation in cancer therapy in recent years, but it is accompanied by various unique immune-related adverse events (irAEs). Among these irAEs, anaphylactic shock is very rare. Here, we report a case of a patient who developed anaphylactic shock after receiving one dose of atezolizumab. A 74-year-old male patient with small cell lung cancer experienced recurrence 10 years after surgery. After one cycle of treatment, the patient developed a grade 2 rash and recovered after receiving oral methylprednisolone tablets. In the second cycle, atezolizumab was discontinued. Then, the patient was scheduled to receive atezolizumab plus carboplatin and etoposide again after three weeks, but approximately three minutes after an intravenous infusion of atezolizumab, the patient developed signs and symptoms of anaphylactic shock, such as dyspnea, cold limbs, and loss of consciousness. At this point, the infusion was immediately stopped, and a normal saline infusion was administered. Meanwhile, ECG monitoring, supplemental humidified high-flow supplemental 100% oxygen, epinephrine, dopamine, hormone treatment with methylprednisolone, and other anti-shock treatments were carried out. For better recuperation, this patient was transferred to the intensive care unit for further treatment and was discharged two days later. Anaphylactic shock develops rapidly and is also a very severe complication. Prompt detection, diagnosis, and therapeutic intervention are the basics for survival.


Subject(s)
Anaphylaxis/chemically induced , Antibodies, Monoclonal, Humanized/adverse effects , Immune Checkpoint Inhibitors/adverse effects , Lung Neoplasms/drug therapy , Small Cell Lung Carcinoma/drug therapy , Aged , Antibodies, Monoclonal, Humanized/therapeutic use , Humans , Immune Checkpoint Inhibitors/therapeutic use , Male
3.
J Enzyme Inhib Med Chem ; 37(1): 462-471, 2022 Dec.
Article in English | MEDLINE | ID: mdl-35012386

ABSTRACT

Kv1.5 potassium channel, encoded by KCNA5, is a promising target for the treatment of atrial fibrillation, one of the common arrhythmia. A new series of arylmethylpiperidines derivatives based on DDO-02001 were synthesised and evaluated for their ability to inhibit Kv1.5 channel. Among them, compound DDO-02005 showed good inhibitory activity (IC50 = 0.72 µM), preferable anti-arrhythmic effects and favoured safety. These results indicate that DDO-02005 can be a promising Kv1.5 inhibitor for further studies.


Subject(s)
Drug Design , Kv1.5 Potassium Channel/antagonists & inhibitors , Piperidines/pharmacology , Potassium Channel Blockers/pharmacology , Dose-Response Relationship, Drug , Humans , Kv1.5 Potassium Channel/metabolism , Molecular Structure , Piperidines/chemical synthesis , Piperidines/chemistry , Potassium Channel Blockers/chemical synthesis , Potassium Channel Blockers/chemistry , Structure-Activity Relationship
4.
J Mol Cell Cardiol ; 112: 123-130, 2017 11.
Article in English | MEDLINE | ID: mdl-28822805

ABSTRACT

The cardiac transverse (T)-tubule membrane system is the safeguard for cardiac function and undergoes dramatic remodeling in response to cardiac stress. However, the mechanism by which cardiomyocytes repair damaged T-tubule network remains unclear. In the present study, we tested the hypothesis that MG53, a muscle-specific membrane repair protein, antagonizes T-tubule damage to protect against maladaptive remodeling and thereby loss of excitation-contraction coupling and cardiac function. Using MG53-knockout (MG53-KO) mice, we first established that deficiency of MG53 had no impact on maturation of the T-tubule network in developing hearts. Additionally, MG53 ablation did not influence T-tubule integrity in unstressed adult hearts as late as 10months of age. Following left ventricular pressure overload-induced cardiac stress, MG53 protein levels were increased by approximately three-fold in wild-type mice, indicating that pathological stress induces a significant upregulation of MG53. MG53-deficient mice had worsened T-tubule disruption and pronounced dysregulation of Ca2+ handling properties, including decreased Ca2+ transient amplitude and prolonged time to peak and decay. Moreover, MG53 deficiency exacerbated cardiac hypertrophy and dysfunction and decreased survival following cardiac stress. Our data suggest MG53 is not required for T-tubule development and maintenance in normal physiology. However, MG53 is essential to preserve T-tubule integrity and thereby Ca2+ handling properties and cardiac function under pathological cardiac stress.


Subject(s)
Carrier Proteins/metabolism , Myocardium/metabolism , Myocardium/pathology , Sarcolemma/metabolism , Animals , Calcium Signaling , Down-Regulation , Excitation Contraction Coupling , Heart/embryology , Male , Membrane Proteins , Mice, Inbred C57BL , Mice, Knockout , Myocytes, Cardiac/metabolism , Sarcolemma/ultrastructure , Sodium-Calcium Exchanger/metabolism
5.
Cytotherapy ; 19(5): 603-616, 2017 05.
Article in English | MEDLINE | ID: mdl-28285950

ABSTRACT

BACKGROUND AIMS: Intrauterine adhesion (IUA) is a common uterine cavity disease characterized by the unsatisfactory regeneration of damaged endometria. Recently, stem cell transplantation has been proposed to promote the recovery process. Here we investigated whether human amniotic mesenchymal stromal cells (hAMSCs), a valuable resource for transplantation therapy, could improve endometrial regeneration in rodent IUA models. METHODS: Forty female Sprague-Dawley rats were randomly assigned to five groups: normal, sham-operated, mechanical injury, hAMSC transplantation, and negative control group. One week after intervention and transplantation, histological analyses were performed, and immunofluorescent and immunohistochemical expression of cell-specific markers and messenger RNA expression of cytokines were measured. RESULTS: Thicker endometria, increased gland numbers and fewer fibrotic areas were found in the hAMSC transplantation group compared with the mechanical injury group. Engraftment of hAMSCs was detected by the presence of anti-human nuclear antigen-positive cells in the endometrial glands of the transplantation uteri. Transplantation of hAMSCs significantly decreased messenger RNA levels of pro-inflammatory cytokines (tumor necrosis factor-α and interleukin-1ß), and increased those of anti-inflammatory cytokines (basic fibroblast growth factor, and interleukin-6) compared with the injured uterine horns. Immunohistochemical expression of endometrial epithelial cells was revealed in specimens after hAMSC transplantation, whereas it was absent in the mechanically injured uteri. CONCLUSIONS: hAMSC transplantation promotes endometrial regeneration after injury in IUA rat models, possibly due to immunomodulatory properties. These cells provide a more easily accessible source of stem cells for future research into the impact of cell transplantation on damaged endometria.


Subject(s)
Amnion/cytology , Endometrium/pathology , Mesenchymal Stem Cell Transplantation , Mesenchymal Stem Cells/cytology , Regeneration , Tissue Adhesions/therapy , Animals , Cells, Cultured , Disease Models, Animal , Female , Fibroblast Growth Factor 2/genetics , Fibroblast Growth Factor 2/metabolism , Fluorescent Antibody Technique , Humans , Interleukin-1beta/genetics , Interleukin-1beta/metabolism , Interleukin-6/genetics , Interleukin-6/metabolism , Rats, Sprague-Dawley , Tissue Adhesions/pathology , Tumor Necrosis Factor-alpha/genetics , Tumor Necrosis Factor-alpha/metabolism
6.
Cells ; 13(17)2024 Sep 09.
Article in English | MEDLINE | ID: mdl-39273080

ABSTRACT

Pericytes are versatile cells integral to the blood vessel walls of the microcirculation, where they exhibit specific stem cell traits. They are essential in modulating blood flow, ensuring vascular permeability, and maintaining homeostasis and are involved in the tissue repair process. The human endometrium is a unique and complex tissue that serves as a natural scar-free healing model with its cyclical repair and regeneration process every month. The regulation of pericytes has gained increasing attention due to their involvement in various physiological and pathological processes. However, endometrial pericytes are less well studied compared to the pericytes in other organs. This review aims to provide a comprehensive overview of endometrial pericytes, with a focus on elucidating their physiological function and potential implications in uterine disorders.


Subject(s)
Endometrium , Pericytes , Uterine Diseases , Humans , Pericytes/metabolism , Endometrium/metabolism , Endometrium/physiology , Female , Uterine Diseases/pathology , Uterine Diseases/physiopathology
7.
Bioorg Med Chem ; 21(9): 2495-502, 2013 May 01.
Article in English | MEDLINE | ID: mdl-23538234

ABSTRACT

A series of novel hybrids of natural isochroman-4-one bearing isopropanolamine moiety were designed, synthesized and evaluated for their antihypertensive activity. It was found that compound IIId, prepared by hybridizing N-isopropyl substituted isopropanolamine functionality to a phenolic oxygen of isochroman-4-one, exhibited potent ß(1)-adrenoceptor blocking effect comparable to the well-known antihypertensive drug propranolol. Additionally, IIId significantly reduced the systolic and diastolic blood pressure in SHRs by over 40%, which was obviously stronger than the lead compounds 7,8-dihydroxy-3-methyl-isochroman-4-one (XJP) and its analogue XJP-B. Overall, IIId may be a promising antihypertensive candidate for further investigation.


Subject(s)
Adrenergic beta-Antagonists/pharmacology , Antihypertensive Agents/pharmacology , Chromones/chemistry , Hypertension/drug therapy , Propanolamines/pharmacology , Adrenergic beta-Antagonists/chemical synthesis , Adrenergic beta-Antagonists/chemistry , Animals , Antihypertensive Agents/chemical synthesis , Antihypertensive Agents/chemistry , Blood Pressure/drug effects , Dose-Response Relationship, Drug , Male , Propanolamines/chemical synthesis , Propanolamines/chemistry , Rats , Rats, Sprague-Dawley , Receptors, Adrenergic, beta/metabolism , Structure-Activity Relationship
8.
Bioorg Med Chem ; 21(21): 6466-76, 2013 Nov 01.
Article in English | MEDLINE | ID: mdl-24071446

ABSTRACT

Atrial fibrillation (AF) is one of the common arrhythmias that threaten human health. Kv1.5 potassium channel is reported as an efficacious and safe target for the treatment of AF. In this paper, we designed and synthesized three series of compounds through modifying the lead compound RH01617 that was screened out by the pharmacophore model we reported earlier. All of the compounds were evaluated by the whole-patch lamp technology and most of them possessed potent inhibitory activities against Kv1.5. Compounds IIIi and IIIl were evaluated for the target selectivity as well as the pharmacodynamic effects in an isolated rat model. Due to the promising pharmacological behavior, compound IIIl deserves further pharmacodynamic and pharmacokinetic evaluations.


Subject(s)
Drug Design , Indoles/chemistry , Kv1.5 Potassium Channel/antagonists & inhibitors , Potassium Channel Blockers/chemistry , Animals , HEK293 Cells , Half-Life , Heart/drug effects , Humans , Hydrazones/chemical synthesis , Hydrazones/chemistry , Hydrazones/pharmacokinetics , Indoles/chemical synthesis , Indoles/pharmacokinetics , Kv1.5 Potassium Channel/genetics , Kv1.5 Potassium Channel/metabolism , Male , Potassium Channel Blockers/chemical synthesis , Potassium Channel Blockers/pharmacokinetics , Protein Binding , Rats , Rats, Sprague-Dawley , Structure-Activity Relationship
9.
J Stomatol Oral Maxillofac Surg ; 124(1S): 101301, 2023 02.
Article in English | MEDLINE | ID: mdl-36182076

ABSTRACT

OBJECTIVE: To investigate the promote healing and analgesic effects of NAHAO® Brand Nazhen oral antibacterial care solution (NAHAO® spray) on the 5-fluorouracil-induced oral mucositis in rats. MATERIAL AND METHOD: Sixty male SD rats were randomly divided into normal group, model group, recombinant human epidermal growth factor (rhEGF) group, NAHAO® spray group, and 1/3 concentration of NAHAO® spray group. 5-FU was injected intraperitoneally on the first and third days of the experimental model, and OM was induced using mechanical trauma on the third and fifth days. Wound healing quality was assessed by the appearance of mucosa and histological images on day6 and day10. Pain is measured by facial grooming behavior stimulated by capsaicin, the alternation of body weight and food intake was also recorded to reflect the OM pain. To examine the involvement of the cyclooxygenase pathway in the mechanism underlying oral mucositis, we detected the expression of cyclooxygenase2(COX-2) and matrix metalloproteinase 9(MMP9) via immunohistochemical staining and determined the PGE2 concentrations in rats' serum during healing of oral mucositis. RESULTS: NAHAO® spray attenuated pathological damage and reduced pain sensitivity effectively. COX-2 expression levels were inhibited in the NAHAO® spray-treated group. The concentration of PGE2 and the expression of MMP9 were inhibited in NAHAO®-treated rats. Compared with normal rats, the elevated rubbing time following capsaicin stimulation in the model was completely inhibited after being treated with NAHAO® spray. CONCLUSION: NAHAO® spray alleviated OM-induced pain and promoted wound healing partly by inhibiting the cyclooxygenase-related pathway.


Subject(s)
Matrix Metalloproteinase 9 , Stomatitis , Humans , Male , Rats , Animals , Cyclooxygenase 2/adverse effects , Cyclooxygenase 2/metabolism , Hydrogels/adverse effects , Capsaicin/adverse effects , Dinoprostone/adverse effects , Rats, Sprague-Dawley , Stomatitis/chemically induced , Stomatitis/drug therapy , Fluorouracil/adverse effects , Pain , Wound Healing
10.
Cardiovasc Ther ; 2023: 8811996, 2023.
Article in English | MEDLINE | ID: mdl-37187923

ABSTRACT

Background: Atrial fibrillation (AF) is the most common arrhythmia in clinical. Atrial fibrosis is a hallmark feature of atrial structural remodeling in AF, which is regulated by the TGF-ß1/Smad3 pathway. Recent studies have implicated that miRNAs are involved in the process of AF. However, the regulatory mechanisms of miRNAs remain largely unknown. This study is aimed at investigating the function and regulatory network of miR-135a in AF. Methods: In vivo, the plasma was collected from patients with AF and non-AF subjects. Adult SD rats were induced by acetylcholine (ACh) (66 µg/ml)-CaCl2 (10 mg/ml) to establish an AF rat model. In vitro, atrial fibroblasts (AFs), isolated from adult SD rats, were treated with high-frequency electrical stimulation (HES) (12 h) and hypoxia (24 h) to mimic the AF and atrial fibrosis, respectively. miR-135a expression was detected through quantitative real-time polymerase chain reaction (qRT-PCR). The association between miR-135a and Smad3 was speculated by the TargetScan database and confirmed by the luciferase reporter assay. Fibrosis-related genes, Smad3, and TRPM7 were all assessed. Results: The expression of miR-135a was markedly decreased in the plasma of AF patients and AF rats, which was consistent with that in HES-treated and hypoxia-treated AFs. Smad3 was identified as a target of miR-135a. the downregulation of miR-135a was associated with the enhancement of Smad3/TRPM7 expressions in AFs. Additionally, the knockdown of Smad3 significantly reduced the expression of TRPM7 and further inhibited atrial fibrosis. Conclusions: Our study demonstrates that miR-135a regulates AF via Smad3/TRPM7, which is a potential therapeutic target for AF.


Subject(s)
Atrial Fibrillation , MicroRNAs , Smad3 Protein , Animals , Rats , Fibrosis , MicroRNAs/metabolism , Rats, Sprague-Dawley , TRPM Cation Channels , Smad3 Protein/metabolism
11.
Nutrients ; 15(24)2023 Dec 18.
Article in English | MEDLINE | ID: mdl-38140398

ABSTRACT

BACKGROUND/AIM: The impact of myocardial stressors such as high-fat diet (HFD) and pressure overload has been extensively studied. Toll-like receptor 4 (TLR4) deficiency has been suggested to have a protective role in response to these stressors, although some conflicting data exist. Furthermore, there is limited information about the role of TLR4 on cardiac remodeling in response to long-term exposure to stressors. This study aims to investigate the effects of TLR4 deficiency on cardiac histology and physiology in response to chronic stressors. METHODS: TLR4-deficient (TLR4-/-) and wild-type (WT) mice were subjected to either HFD or a normal diet (ND) for 28 weeks. Another group underwent abdominal aortic constriction (AAC) or a sham procedure and was monitored for 12 weeks. Inflammatory markers, histology, and echocardiography were used to assess the effects of these interventions. RESULTS: TLR4-/- mice exhibited reduced cardiac hypertrophy and fibrosis after long-term HFD exposure compared to ND without affecting cardiac function. On the other hand, TLR4 deficiency worsened cardiac function in response to AAC, leading to decreased ejection fraction (EF%) and increased end-systolic volume (ESV). CONCLUSIONS: TLR4 deficiency provided protection against HFD-induced myocardial inflammation but impaired hemodynamic cardiac function under pressure overload conditions. These findings highlight the crucial role of TLR4 and its downstream signaling pathway in maintaining cardiac output during physiologic cardiac hypertrophy in response to pressure overload.


Subject(s)
Cardiomegaly , Diet, High-Fat , Toll-Like Receptor 4 , Animals , Mice , Cardiomegaly/genetics , Cardiomegaly/metabolism , Diet, High-Fat/adverse effects , Heart , Mice, Inbred C57BL , Mice, Knockout , Toll-Like Receptor 4/genetics , Toll-Like Receptor 4/metabolism
12.
J Stomatol Oral Maxillofac Surg ; 124(6S): 101568, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37524129

ABSTRACT

OBJECTIVE: To evaluate the efficacy of NAHAO® oral mucosal antibacterial care solution (NAHAO® spray) on attenuating oral mucositis (OM) symptoms and related mechanisms investigation. MATERIAL AND METHODS: Experimental OM models were established by acetic acid and 5-fluorouracil combined with mechanical trauma. We investigated spontaneous pain of conscious OM rats after using NAHAO®. The expression of NF-κB in affected trigeminal ganglion was measured by western blot. In clinical study, 60 patients who developed post-treatment OM of grade 2 or above or persistent mucosal pain with a score equal to or greater than 4 points were selected. All patients were required to receive NAHAO® spray 8 times a day and were examined for OM degrees and oral mucosal pain scores before and after application. RESULTS: Experimental data from experimental model suggested that clinical efficacy of NAHAO® spray was involved in inflammation inhibition via NF-κB pathway. The results of clinical study showed that NAHAO® spray improved the symptoms of OM, there is statistically significant difference in oral mucosal pain scores after treated with NAHAO, and the dietary restrictions were also improved. CONCLUSION: NAHAO® spray alleviates pain and improves the diet situation in OM patients, which is partly mediated through the inhibition of NF-κB pathway.


Subject(s)
Hydrogels , Stomatitis , Humans , Rats , Animals , Hydrogels/adverse effects , NF-kappa B/therapeutic use , Stomatitis/drug therapy , Stomatitis/chemically induced , Pain/drug therapy , Chemoradiotherapy/methods
13.
Front Endocrinol (Lausanne) ; 14: 1026168, 2023.
Article in English | MEDLINE | ID: mdl-36967761

ABSTRACT

Objective: Bromocriptine treatment has been shown to reduce menstrual bleeding and pain in women with adenomyosis in a pilot clinical trial. The underlying mechanism contributing to the treatment effect is however unknown. The purpose of this study was to explore the effect of bromocriptine on the proliferation and migration properties of the endometrium in women with adenomyosis, by assessing cellular and molecular changes after six months of vaginal bromocriptine treatment. Methods: Endometrial specimens were collected during the proliferative phase from women with adenomyosis (n=6) before (baseline) and after six months of treatment with vaginal bromocriptine. Immunohistochemistry was used to determine changes in the protein expression of Ki67 in the endometrium of women with adenomyosis. Primary endometrial stromal cells isolated at baseline were expanded in vitro and exposed to different doses of bromocriptine to determine the optimal half-maximum inhibitory concentration (IC50) using CellTiter-Blue® Cell Viability Assay. Cell proliferation was assessed by bromodeoxyuridine ELISA assay and Ki67 gene expression was checked by real-time PCR. The migratory ability of endometrial stromal cells was determined by wound healing and transwell migration assays. Small RNA sequencing was applied on tissues collected from women with adenomyosis before and after bromocriptine treatment to identify differentially expressed microRNAs (miRNAs) after bromocriptine treatment. Bioinformatic methods were used for target gene prediction and the identification of biological pathways by enrichment procedures. Results: Vaginal bromocriptine treatment reduced the Ki67 protein expression in the endometrium of women with adenomyosis and did not change the prolactin mRNA expression and protein concentration of prolactin in endometrial tissues. Bromocriptine significantly inhibited the proliferative and migrative abilities of endometrial stromal cells derived from women with adenomyosis in vitro. Moreover, small RNA sequencing revealed 27 differentially expressed miRNAs between the endometrium of women with adenomyosis before and after six months of vaginal bromocriptine treatment. KEGG pathway analysis on targeted genes of 27 miRNAs showed that several signaling pathways associated with cell proliferation and apoptosis were enriched after bromocriptine treatment. Conclusion: Bromocriptine treatment exhibits an anti-proliferative effect in the endometrium of women with adenomyosis in vivo and in vitro. Bromocriptine might inhibit the proliferation of endometrial tissue in adenomyosis in part through the regulation of dysregulated microRNAs and proliferation-associated signaling pathways.


Subject(s)
Adenomyosis , MicroRNAs , Humans , Female , Adenomyosis/drug therapy , Bromocriptine/pharmacology , Bromocriptine/therapeutic use , Ki-67 Antigen/metabolism , Prolactin/metabolism , Endometrium/metabolism , MicroRNAs/genetics , MicroRNAs/metabolism , Cell Proliferation
14.
Acta Pharmacol Sin ; 33(5): 625-34, 2012 May.
Article in English | MEDLINE | ID: mdl-22555370

ABSTRACT

AIM: To investigate the protection of pulmonary arterial rings and cardiac myocytes of rats by raisanberine (RS), a derivative of berberine, against hypoxia injury and to elucidate the action mechanisms. METHODS: Adult SD rats were exposed to intermittent hypoxia for 17 d or 28 d. The pulmonary arterial rings were isolated and vascular activity was measured using a transducer and computer-aided system. The difference in the tension produced by phenylephrine in the presence and absence of L-nitroarginine (10 µmol/L) was referred to as the NO bioavailability; the maximum release of NO was assessed by the ratio of the maximal dilatation caused by ACh to those caused by sodium nitroprusside. After the lungs were fixed, the internal and the external diameters of the pulmonary arterioles were measured using a graphic analysis system. Cultured cardiac myocytes from neonatal rats were exposed to H(2)O(2) (10 µmol/L) to mimic hypoxia injury. ROS generation and [Ca(2+)](i) level in the myocytes were measured using DHE and Fluo-3 fluorescence, respectively. RESULTS: Oral administration of RS (80 mg/kg), the NADPH oxidase inhibitor apocynin (APO, 80 mg/kg) or Ca(2+) channel blocker nifedipine (Nif, 10 mg/kg,) significantly alleviated the abnormal increase in the vasoconstriction force and endothelium-related vasodilatation induced by the intermittent hypoxia. The intermittent hypoxia markedly decreased the NO bioavailability and maximal NO release from pulmonary arterial rings, which were reversed by APO or RS administration. However, RS administration did not affect the NO bioavailability and maximal NO release from pulmonary arterial rings of normal rats. RS, Nif or APO administration significantly attenuated the pulmonary arteriole remodeling. Treatment of cultured cardiac myocytes with RS (10 µmol/L) suppressed the ROS generation and [Ca(2+)](i) increase induced by H(2)O(2), which were comparable to those caused by APO (10 µmol/L) or Nif (0.1 µmol/L). CONCLUSION: Raisanberine relieved hypoxic/oxidant insults to the pulmonary artery and cardiac myocytes of rats by suppressing activated NADPH oxidase and increased calcium influx.


Subject(s)
Antioxidants/pharmacology , Berberine/analogs & derivatives , Berberine/pharmacology , Calcium Signaling/drug effects , Hypoxia/drug therapy , Myocytes, Cardiac/drug effects , NADPH Oxidases/antagonists & inhibitors , Pulmonary Artery/drug effects , Administration, Oral , Animals , Antioxidants/administration & dosage , Arterioles/drug effects , Arterioles/enzymology , Berberine/administration & dosage , Calcium Channel Blockers/pharmacology , Calcium Channels/drug effects , Calcium Channels/metabolism , Cells, Cultured , Cytoprotection , Disease Models, Animal , Dose-Response Relationship, Drug , Down-Regulation , Enzyme Inhibitors/pharmacology , Hypoxia/enzymology , Hypoxia/pathology , Hypoxia/physiopathology , Male , Myocytes, Cardiac/enzymology , NADPH Oxidases/metabolism , Nitric Oxide/metabolism , Oxidative Stress/drug effects , Pulmonary Artery/enzymology , Pulmonary Artery/pathology , Pulmonary Artery/physiopathology , Rats , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolism , Time Factors , Vasoconstriction/drug effects , Vasoconstrictor Agents/pharmacology , Vasodilator Agents/pharmacology
15.
Shanghai Kou Qiang Yi Xue ; 31(5): 544-549, 2022 Oct.
Article in Zh | MEDLINE | ID: mdl-36758606

ABSTRACT

PURPOSE: To provide a reference basis for clinical selection of a reasonable and effective root canal treatment by comparing the short-term clinical efficacy of three root canal filling methods in the treatment of chronic periapical inflammation. METHODS: One hundred and twenty patients with chronic periapical inflammation who received root canal filling between October 2019 and October 2020 were randomly divided into 3 groups, with 40 patients in each group. All patients received root canal filling, group A was filled with iRoot SP paste by matched-taper single cone obturation technique, group B was filled with AH-plus paste by warm vertical condensation, and group C filled with AH-plus paste by cold lateral condensation. Root canal filling time in the three groups was calculated, pain score 24 h after treatment was determined using visual analogue scale/score(VAS), and periapical index(PAI) was used to evaluate radiographs. SPSS 22.0 statistical software was applied for data analysis. RESULTS:Root canal filling times in the three groups were (75.50±7.44) s in group A, (85.38±3.46) s in group B and (102.33±3.32) s in group C, the differences were statistically significant (P<0.05); the incidence of postoperative pain in the three groups was 25% in group A, 25% in group B and 32.5% in group C, the difference was not statistically significant(P>0.05). There was no significant difference between group A and group B, but significant difference existed between group A, group B and group C. The results of comparison of PAI scores showed a time effect was F=498.93, P<0.001, suggesting significant difference in total PAI scores at different time points; a group effect was F=0.91, P=0.406, suggesting no significant difference in total PAI scores of the 3 groups; an interaction effect of time and group was F=0.44, P=0.777, suggesting that there was no significant difference in total PAI scores of the 3 groups at the time points. The total effective rate at 3 and 12 months was 97.5%, 97.3% in group A, 97.5%, 97.2% in group B and 90%, 91.9% in group C, the difference was not statistically significant(P>0.05). CONCLUSIONS: Compared with the other 2 root canal filling methods, the iROOT SP paste matched-taper single cone obturation technique is clinically effective in terms of time saving and increasing the comfort of the patients' visit.


Subject(s)
Gutta-Percha , Root Canal Filling Materials , Humans , Dental Pulp Cavity , Root Canal Preparation/methods , Root Canal Filling Materials/adverse effects , Root Canal Obturation/methods , Inflammation
16.
Biol Pharm Bull ; 34(10): 1596-601, 2011.
Article in English | MEDLINE | ID: mdl-21963501

ABSTRACT

The objective of the present study was to evaluate the cardiovascular protective effects of Danshensu, a water-soluble active component of Danshen, in spontaneously hypertensive rats (SHR). SHR (male, 9 weeks old, n=30) were divided into three groups: 1) saline control (n=10); 2) a Danshensu (10 mg/kg/d, intraperitoneally (i.p.)) treatment group (n=10); and 3) a Valsartan (10 mg/kg/d, intragastrically (i.g.)) treatment group (n=10). Age-matched Wistar-Kyoto rats (n=10) were used as normotensive controls. Saline and drug treatments were administered for 6 weeks. When the rats were 15 weeks old, their hearts were excised and arrhythmias were induced by an ex vivo ischemia/reperfusion protocol. The heart weight to body weight index was significantly increased in SHR, and this increase was attenuated with Danshensu treatment (both p<0.05). Systolic blood pressure and diastolic blood pressure were also decreased with Danshensu treatment, from 145±3 and 103±10 mmHg to 116±7 and 87±2 mmHg in SHR and Danshensu-treated groups, respectively (both p<0.05). The incidences of ventricular tachycardia and ventricular fibrillation decreased from 100 to 50% and 30% in SHR, respectively, with Danshensu treatment (both p<0.05). Serum nitric oxide content and inducible nitric oxide synthase activity were significantly increased with Danshensu (both p<0.05). In addition, Danshensu increased the K(+) current density and Ca(2+) activated K(+) channel current density of mesenteric vascular smooth muscle cells isolated from SHRs. Together, these results demonstrate that Danshensu imparts cardiovascular protection by modifying vascular responses during the progression of hypertension.


Subject(s)
Cardiotonic Agents/pharmacology , Hypertension/prevention & control , Lactates/pharmacology , Large-Conductance Calcium-Activated Potassium Channels/physiology , Phytotherapy , Salvia miltiorrhiza , Animals , Antihypertensive Agents/pharmacology , Arrhythmias, Cardiac/physiopathology , Arrhythmias, Cardiac/prevention & control , Blood Pressure/drug effects , Body Weight/drug effects , Cardiotonic Agents/chemistry , Cardiovascular System/physiopathology , Chronic Disease/drug therapy , Drug Administration Schedule , Drug Evaluation, Preclinical , Heart/physiopathology , Heart Function Tests/drug effects , Hypertension/drug therapy , Hypertension/physiopathology , Lactates/chemistry , Male , Mesenteric Arteries/cytology , Mesenteric Arteries/drug effects , Molecular Targeted Therapy , Muscle, Smooth, Vascular/cytology , Muscle, Smooth, Vascular/drug effects , Nitric Oxide Synthase Type II/blood , Patch-Clamp Techniques , Plant Preparations/chemistry , Plant Preparations/pharmacology , Plant Roots , Rats , Rats, Inbred SHR , Rats, Inbred WKY , Tetrazoles/pharmacology , Valine/analogs & derivatives , Valine/pharmacology , Valsartan
17.
Yao Xue Xue Bao ; 46(1): 12-8, 2011 Jan.
Article in Zh | MEDLINE | ID: mdl-21465803

ABSTRACT

Due to the complicated pathogenesis of cardiac arrhythmia, the safe and effective therapeutic strategies for cardiac arrhythmia remain an urgent medical problems in the recent years. In this paper, we introduced the research practice of anti-arrhythmic agents targeting on potassium ion channel. The research progress of anti-arrhythmic agents in up-to-date literatures were also reviewed and prospected.


Subject(s)
Anti-Arrhythmia Agents/pharmacology , Arrhythmias, Cardiac/drug therapy , Potassium Channel Blockers/pharmacology , Potassium Channels/drug effects , Amiodarone/analogs & derivatives , Amiodarone/chemistry , Amiodarone/pharmacology , Amiodarone/therapeutic use , Animals , Anti-Arrhythmia Agents/chemistry , Anti-Arrhythmia Agents/therapeutic use , Arrhythmias, Cardiac/physiopathology , Dronedarone , Humans , Hydantoins , Imidazolidines/chemistry , Imidazolidines/pharmacology , Imidazolidines/therapeutic use , Molecular Structure , Piperazines/chemistry , Piperazines/pharmacology , Piperazines/therapeutic use , Potassium Channel Blockers/therapeutic use
18.
Front Cell Dev Biol ; 9: 701547, 2021.
Article in English | MEDLINE | ID: mdl-35059392

ABSTRACT

Diabetic nephropathy (DN) is a serious kidney-related complication of both type 1 and type 2 diabetes mellitus (T1DM, T2DM) and the second major cause of end-stage kidney disease. DN can lead to hypertension, edema, and proteinuria. In some cases, DN can even progress to kidney failure, a life-threatening condition. The precise etiology and pathogenesis of DN remain unknown, although multiple factors are believed to be involved. The main pathological manifestations of DN include mesangial expansion, thickening of the glomerular basement membrane, and podocyte injury. Eventually, these pathological manifestations will lead to glomerulosclerosis, thus affecting renal function. There is an urgent need to develop new strategies for the prevention and treatment of DN. Existing evidence shows that the Wnt signaling cascade plays a key role in regulating the development of DN. Previous studies focused on the role of the Wnt canonical signaling pathway in DN. Subsequently, accumulated evidence on the mechanism of the Wnt non-canonical signaling indicated that Wnt/Ca2+ and Wnt/PCP also have essential roles in the progression of DN. In this review, we summarize the specific mechanisms of Wnt signaling in the occurrence and development of DN in podocyte injury, mesangial cell injury, and renal fibrosis. Also, to elucidate the significance of the Wnt canonical pathway in the process of DN, we uncovered evidence supporting that both Wnt/PCP and Wnt/Ca2+ signaling are critical for DN development.

19.
Front Cell Dev Biol ; 9: 760035, 2021.
Article in English | MEDLINE | ID: mdl-34778271

ABSTRACT

Heart failure caused by cardiac fibrosis has become a major challenge of public health worldwide. Cardiomyocyte programmed cell death (PCD) and activation of fibroblasts are crucial pathological features, both of which are associated with aberrant Ca2+ influx. Transient receptor potential cation channel subfamily M member 7 (TRPM7), the major Ca2+ permeable channel, plays a regulatory role in cardiac fibrosis. In this study, we sought to explore the mechanistic details for sacubitril, a component of sacubitril/valsartan, in treating cardiac fibrosis. We demonstrated that sacubitril/valsartan could effectively ameliorate cardiac dysfunction and reduce cardiac fibrosis induced by isoprotereno (ISO) in vivo. We further investigated the anti-fibrotic effect of sacubitril in fibroblasts. LBQ657, the metabolite of sacubitril, could significantly attenuate transforming growth factor-ß 1 (TGF-ß1) induced cardiac fibrosis by blocking TRPM7 channel, rather than suppressing its protein expression. In addition, LBQ657 reduced hypoxia-induced cardiomyocyte PCD via suppression of Ca2+ influx regulated by TRPM7. These findings suggested that sacubitril ameliorated cardiac fibrosis by acting on both fibroblasts and cardiomyocytes through inhibiting TRPM7 channel.

20.
J Ethnopharmacol ; 249: 112404, 2020 Mar 01.
Article in English | MEDLINE | ID: mdl-31739105

ABSTRACT

ETHNOPHARMACOLOGICAL RELEVANCE: Cardiac fibrosis is a common characteristic of many cardiac diseases. Our previous results showed that TRPM7 channel played an important role in the fibrosis process. MicroRNA-135a was reported to get involved in the fibrotic process. Astragalus membranaceus (Fisch.) Bunge was widely used in Chinese traditional medicine and showed cardiac protective effects in previous researches. Astragaloside IV(ASG), which is regarded as the most important ingredient of Astragalus, has been showed the effect of cardiac protection via various mechanisms, while no data suggested its action related to miRNAs regulation. AIM OF THE STUDY: The objective of this article is to investigate the inhibition effect of ASG on cardiac fibrosis through the miR-135a-TRPM7-TGF-ß/Smads pathway. MATERIALS AND METHODS: We extracted the active components from herb according to the paper and measured the content of ASG from the mixture via HPLC. The inhibition potency of cardiac hypertrophy between total extract of Astragalus and ASG was compared. SD rats were treated with ISO (5 mg/kg/day) subcutaneously (s.c.) for 14 days, ASG (10 mg/kg/d) and Astragalus extract (AE) (4.35 g/kg/d, which contained about ASG 10 mg) were given p.o. from the 6th day of the modeling. Cardiac fibroblasts (CFs) of neonatal rats were incubated with ISO (10 µM) and treated with ASG (10 µM) simultaneously for 24 h. RESULTS: The results showed that both AE and ASG treatment reduced the TRPM7 expression from the gene level and inhibited cardiac fibrosis. ASG group showed similar potency as the AE mixture. ASG treatment significantly decreased the current, mRNA and protein expression of TRPM7 which was one of targets of miR-135a. The activation of TGF-ß/Smads pathway was suppressed and the expression of α-SMA and Collagen I were also decreased obviously. In addition, our results showed that there was a positive feedback between the activation of TGF-ß/Smads pathway and the elevation of TRPM7, both of which could promote the development of myocardial fibrosis. CONCLUSIONS: AE had the effect of cardiac fibrosis inhibition and decreased the mRNA expression of TRPM7. ASG, as one of the effective ingredients of AE, showed the same potency when given the same dose. ASG inhibited cardiac fibrosis by targeting the miR-135a-TRPM7-TGF-ß/Smads pathway.


Subject(s)
Cardiomyopathy, Hypertrophic/drug therapy , Myocardium/pathology , Plant Extracts/pharmacology , Saponins/pharmacology , Signal Transduction/drug effects , Triterpenes/pharmacology , Animals , Animals, Newborn , Astragalus Plant/chemistry , Cardiomyopathy, Hypertrophic/chemically induced , Cardiomyopathy, Hypertrophic/genetics , Cardiomyopathy, Hypertrophic/pathology , Cells, Cultured , Disease Models, Animal , Fibrosis , Humans , Isoproterenol/toxicity , Male , Medicine, Chinese Traditional/methods , MicroRNAs/metabolism , Myocardium/cytology , Myofibroblasts , Plant Extracts/chemistry , Plant Extracts/isolation & purification , Plant Extracts/therapeutic use , Plant Roots/chemistry , Primary Cell Culture , Rats , Rats, Sprague-Dawley , Saponins/isolation & purification , Saponins/therapeutic use , Signal Transduction/genetics , Smad Proteins/metabolism , TRPM Cation Channels/metabolism , Transforming Growth Factor beta/metabolism , Triterpenes/isolation & purification , Triterpenes/therapeutic use
SELECTION OF CITATIONS
SEARCH DETAIL